Company intelligence / Profile preview

ORPHELIA Pharma

Paris, Ile de France, Franceorphelia-pharma.eu ↗

Ownership: Private
Employees: ~9
Development stage: Commercial

Overview

ORPHELIA Pharma has one drug (Kigabeq®) approved in the European Union and available in several countries. Another product (Kizfizo®), an oral liquid formulation of temozolomide, is currently under EU marketing authorization review[1].

Therapeutic areas: OncologyRare DiseasesNeurologyMetabolic Disorders
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

ORP-010

Unknown

Partnerships

Regional distribution agreements in the European Union and elsewhere, academic and industrial partnerships[1]

Beyond the preview

Go deeper on ORPHELIA Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORPHELIA Pharma.

Explore the full profile